Browsing Tag
DurAVR
3 posts
Anteris names Brent Moen CFO as $260.9m cash pile funds pivotal DurAVR trial
Anteris Technologies Global has appointed former Tactile Systems Technology CFO Brent Moen as finance chief as spending accelerates on its 1,000-patient pivotal DurAVR heart-valve trial and U.S. commercial preparations.
Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments
Edwards and Medtronic own TAVR. Anteris (ASX: AVR) wants in with DurAVR. First US PARADIGM patients enrolled, US$320m raised, and Medtronic is now a shareholder.
Medtronic invests in Anteris (ASX: AVR) to fund DurAVR trial and TAVR platform expansion
Anteris Technologies has raised USD 320M, including USD 90M from Medtronic, to fund its global DurAVR heart valve trial. Read what this means for TAVR competition.